Malcolm Barratt-Johnson
Chief Tech/Sci/R&D Officer at ALBERT LABS INTERNATIONAL CORP.
Net worth: - $ as of 30/05/2024
Malcolm Barratt-Johnson active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ALBERT LABS INTERNATIONAL CORP. | Chief Tech/Sci/R&D Officer | - | - |
NovaBiotics Ltd.
 NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | Director/Board Member | 30/09/2020 | - |
Career history of Malcolm Barratt-Johnson
Statistics
International
| 2 | |
| United Kingdom | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Sectoral
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
| Albert Labs International Corp. | |
NovaBiotics Ltd.
NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | Health Technology |